WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference: H.C. Wainwright 4th Annual Kidney Virtual ConferenceDate:Monday, July 14, 2025Time:1:30pm ETFormat:Fireside ChatWebcast:Link The live webcast ...

ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.What happened: The chronic kidney disease (CKD)-focused company reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial of rilparencel in patients with CKD and diabetes.Rilparencel is an autologous cellular therapy ...

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera (https://immuthera.bio/) in Delaware to expand its presence in the U.S. market. A Pre-IND application was submitted to the FDA.The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on PolTREG’s Pediatric Investigation Plan (PIP) for PTG-007 in pre-symptomatic type 1 diabetes (Stage 1). Gdańsk, Poland – 13 JUNE 2025 – PolTREG S.A. (Warsaw Stock Exch ...

Core Insights - ProKidney Corp. reported financial results for Q1 2025, highlighting its focus on chronic kidney disease (CKD) and upcoming milestones in clinical trials [1][2] Financial Highlights - As of March 31, 2025, ProKidney had cash, cash equivalents, and marketable securities totaling $328.5 million, down from $358.3 million at the end of 2024, which is expected to fund operations into mid-2027 [4][8] - Research and development expenses were $27.3 million for Q1 2025, slightly up from $27.2 million in Q1 2024, with increases in cash compensation and facility costs offset by a decrease in clinical trial costs [5] - General and administrative expenses rose to $14.4 million in Q1 2025 from $12.8 million in Q1 2024, primarily due to higher cash compensation and professional fees [6] - The net loss before noncontrolling interest was $38.0 million for Q1 2025, compared to $35.3 million for the same period in 2024 [7] Clinical Development - The company is approaching key milestones, including the release of full Group 1 data from the Phase 2 REGEN-007 study and a regulatory update on the accelerated approval pathway for rilparencel following a Type B meeting with the FDA [2][8] - Full data from Group 1 of the Phase 2 REGEN-007 study is expected in Q2 2025, involving approximately 20 patients with an average follow-up of 18 months [9] - The Phase 3 REGEN-006 (PROACT 1) clinical trial is ongoing, focusing on patients with type 2 diabetes and advanced CKD, with a total planned enrollment of approximately 685 subjects [10] Company Overview - ProKidney Corp. specializes in cellular therapeutics for chronic kidney disease, with its lead product candidate, rilparencel, being evaluated in late-stage clinical trials [12]

Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significance Statistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell Therapy Patient improvements through two years suggest single dose of Cardi ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Edward Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Joseph Pantginis - H.C. Wainwright Kristen Kluska - Cantor Fitzgerald Catherine Novack - JonesTrading Aydin Huseynov - Ladenburg Madison El-Saadi - B. Riley Securities Operator Good afternoon, ladies and gentlemen, and w ...